CareLit · DOI-Nachweis · Pneumologie
Inhalative application of soluble guanylyl cyclase stimulator BAY 41–8543 for treatement of pulmonary arterial hypertension
DOI 10.1055/s-0030-1251355
Bibliografische Angaben
Nachweis in CareLit
Autor:innenV Amirjanians, B Egemnazarov, A Sydykov, B Kojonazarov, H Luitel, N Weissmann, F Grimminger, W Seeger, R Schermuly, HA Ghofrani
ZeitschriftPneumologie
Ausgabe03/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background. Pulmonary arterial hypertension (PAH) is a devastating disease with a pure outcome. Recently, a new class of medicines has been proposed for treatment of the disease – soluble guanylyl cyclase stimulators. The possible drawback of the drugs is the potential of systemic arterial hypotension. Therefore, we sought to achieve the pulmonary selectivity of the BAY 41–8543 effects by inhalative application. Met…
Zitieren
Zitierempfehlung
V Amirjanians, B Egemnazarov, A Sydykov, B Kojonazarov, H Luitel, N Weissmann, F Grimminger, W Seeger, R Schermuly, HA Ghofrani (2010) Inhalative application of soluble guanylyl cyclase stimulator BAY 41–8543 for treatement of pulmonary arterial hypertension. Pneumologie (03). https://doi.org/10.1055/s-0030-1251355
Mit CareLit weiterarbeiten